Completed NCT00922272
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Little Rock Schizophrenia Drug i A study involving a medication or substance. From 18 Years to 55 Years
Countries United States
Sponsor Shire
Condition Schizophrenia Completed NCT01488929
This study is completed in the United States, in Hungary, in Romania, .... It focuses on schizophrenia.
Multiple locations, including Garden Grove Schizophrenia Drug From 18 Years to 65 Years
Countries United States, Hungary, Romania, ...
Sponsor Targacept Inc.
Condition Schizophrenia Completed NCT01124708
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Bradenton ADHD Drug From 18 Years to 65 Years
Countries United States
Sponsor Targacept Inc.
Condition ADHD Active Not Recruiting NCT05711940
This study is active but not recruiting in the United States, in France, in Canada, .... It focuses on Depression.
Multiple locations, including Gilbert Depression Drug Over 18 Years
Countries United States, France, Canada, ...
Sponsor COMPASS Pathways
Condition Depression Completed NCT02153502
This study is completed in the United States. It is testing AVP-786 for depression.
Multiple locations, including Birmingham Depression Drug Over 18 Years
Countries United States
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Depression Completed NCT05545111
This study is completed in the United States. It is testing NBI-1117568 for schizophrenia.
Multiple locations, including Little Rock Schizophrenia Drug From 18 Years to 55 Years
Countries United States
Sponsor Neurocrine Biosciences
Condition Schizophrenia Completed NCT00301236
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Mesa ADHD Drug From 6 Years to 12 Years
Countries United States
Sponsor Novartis
Condition ADHD Completed NCT00386581
This summary needs review. Please check the official study record and contact the research team for details.
In Moscow ADHD Drug From 6 Years to 16 Years
Countries Russia
Sponsor Eli Lilly and Company
Condition ADHD Ongoing EUCTR 2022-001244-15
This study is ongoing in France. It focuses on Schizophrenia.
In France Schizophrenia Other
Countries France
Sponsor GHU Paris Psychiatrie et Neurosciences
Condition Schizophrenia Terminated NCT02383095
This summary needs review. Please check the official study record and contact the research team for details.
In Strasbourg Schizophrenia Behavioral From 18 Years to 55 Years
Countries France
Sponsor University Hospital, Strasbourg, France
Condition Schizophrenia Completed NCT02667834
This summary needs review. Please check the official study record and contact the research team for details.
In Clermont Schizophrenia Behavioral From 18 Years to 50 Years
Countries France
Sponsor Hôpital le Vinatier
Condition Schizophrenia Completed NCT01516424
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Beijing Schizophrenia Drug From 18 Years to 64 Years
Countries China
Sponsor Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Condition Schizophrenia